Anticancer Therapies – Products

In this article, we take a look at how researchers are tackling some of the challenges that are preventing cell therapies from being more widely used, paying particular attention to cellular immunotherapies for cancer and induced pluripotent stem cel

PHC Corporation’s Biomedical Division announced the commercial launch of LiCellMo, a live cell metabolic analyzer that allows researchers to visualize metabolic changes in cell cultures.

This whitepaper explores the available technologies, key challenges and the growing impact of single-cell cloning.

This application note highlights the features of active-release beads compared to the established passive-release beads for the isolation, activation, cell expansion and desired early memory cell phenotype.

Transgene announces the publication in the Journal for ImmunoTherapy of Cancer (JITC) of a peer-reviewed article which illustrates that TG6050 induces profound immune remodeling of the tumor microenvironment in animal models.

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency.

Touchlight, announced a license agreement with GSK. This agreement grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA™ (doggybone DNA™) technology for the development and production of mRNA-based products.

Harnessing the cytotoxic potential of T cells through immunotherapy has revolutionized cancer treatment, but the effectiveness of T-cell therapeutics is still limited in solid tumors.

This whitepaper explores groundbreaking organ-on-a-chip technology and 3D tissue modeling that is closing the translational gap in cancer drug discovery.

The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy (CAR-T cell therapy) for patients in Estonia.